Participated · Series E · Mar 2026

Monteris Medical develops the NeuroBlate System, a robotically controlled, MR-guided laser ablation platform that enables minimally invasive treatment of brain tumors and drug-resistant epilepsy in patients aged two and older. The technology, deployed in nearly 130 health systems across North America, delivers precise laser energy to destroy abnormal brain tissue while minimizing collateral damage. Clinical studies cited by the company report short hospital stays, low complication rates, and outcomes comparable to open resection. Monteris plans to use new capital to expand its U.S. commercial footprint, advance technology development, conduct additional clinical research, and pursue geographic expansion. Management reports strong operational results with a near-term pathway to profitability and positive cash flow. The NeuroBlate platform is currently the only LITT system with a robotic interface and published prospective clinical data supporting its safety and efficacy.

Led · Debt Financing · Sep 2024

Venus Concept develops medical aesthetic device platforms and hair restoration technologies, including Venus Versa and ARTAS iX. The company operates in over 60 countries and targets demand for non‑invasive and minimally invasive procedures. Management is focused on optimizing the capital structure and streamlining operations to pursue sustained profitability. On September 26, 2024 Venus Concept exchanged $15 million of senior debt for equity as part of that effort. The company issued 203,583 shares of Series Y preferred stock in the transaction. Total debt obligations were reduced to approximately $34.6 million, down from $46 million three months earlier and $74.9 million at the end of 2023. Venus Concept has raised $115.72 million to date, was founded in 2009, and is based in Weston, Florida. Venus Concept Inc. announced receipt of $16.998967 million in funding from Masters Special Situations, LLC, Essex Woodlands Management, Inc., HealthQuest Capital, Masters Capital Management, L.L.C. and other investors. Concurrent with the financing, the company entered into a stock purchase agreement for a non‑brokered private placement. The private placement covers 9,808,418 common shares of par value $0.0001 and 3,790,755 preferred non‑voting shares. The transaction therefore involves issuance of both common and preferred equity securities. The announcement and disclosure focus on the financing and share issuance rather than operational or product details. Venus Concept develops, commercializes, and delivers aesthetic technologies and related practice enhancement services using a subscription-based business model. The company’s devices are designed to expand beyond traditional dermatology and plastic surgery markets into non-traditional settings such as family practice, general practice, internal medicine, obstetrics and gynecology, and medical spas. Venus Concept sells its devices in over 60 countries and operates 27 direct global offices. The company has expanded its subscription platform and employs over 400 global employees. Led by Chairman and CEO Domenic Serafino, Venus Concept plans ongoing product development to serve the aesthetic marketplace. The company intends to use recent funding to grow its subscription business and to expand and mature its direct office footprint. Venus Concept develops and distributes technology devices for skin tightening, body contouring and skin rejuvenation for the face, neck and body. Led by CEO Domenic Serafino, the company markets devices intended for pain-free aesthetic treatments. It operates through 14 offices worldwide. The company received a $20M senior secured term loan to support the ongoing commercialization of its device line. The financing was provided to back sales and commercialization efforts for its portfolio of aesthetic devices. Venus Concept is a leader in the global aesthetics market offering differentiated, comprehensive aesthetic solutions delivered through a partnership model with physicians. The company emphasizes best-in-class patient outcomes and dedicated customer service. Recent shareholder activity brought significant U.S. investor backing and was described by management as transformative. Management changes include Domenic Serafino assuming the role of Chairman and additions of senior regulatory and medical affairs leaders. Co-founder Oded Ron Edoute stepped down as Chairman but will continue working on development of the Chinese and Hong Kong markets. The company is positioning its leadership and investor base to support continued growth in target markets.

Participated · Series A · Dec 2020

SomaLogic develops and commercializes a proprietary proteomics platform built around its SOMAmer protein-binding reagents, which blend attributes of monoclonal antibodies and traditional aptamers. Its flagship SOMAscan assay currently deploys 1,310 different SOMAmer reagents to quantify proteins across a broad concentration range using small sample volumes from multiple biological matrices. These capabilities provide researchers and clinicians with powerful tools for protein biomarker discovery, diagnostics development, and pharmaceutical innovation. The company is led by Chief Executive Officer Byron Hewett and Founder & Chairman Larry Gold, PhD. SomaLogic plans to expand its portfolio of life-science tools and clinical diagnostic products that leverage its core technology. To finance this growth, it is arranging up to $60.5 million in combined debt and equity financing from Visium Healthcare Partners, strengthening its balance sheet for continued R&D and commercialization efforts.

Led · Equity · Aug 2017

Establishment Labs is a global, privately held medical technology company focused on aesthetic technologies and product innovation. Its core offering is the CE-marked Motiva Implants line of ultra-high purity medical-grade silicone breast implants, which are sold in more than 60 countries. The company also markets Divina, a proprietary 3D imaging technology for consultation and surgical planning, and distributes Puregraft, an FDA-cleared and CE-marked fat-purification technology. All of its manufacturing facilities are reported to be compliant with applicable FDA and ISO standards. Management says it will use financing to support R&D into next-generation implants, pursue expanded commercialization in markets where Motiva is approved, and back a proposed FDA trial and entrance into the U.S. market. The company closed a $55 million combined secured credit facility and equity investment to support these initiatives. Establishment Labs is an NYC-based global medical device company focused on breast surgery technologies, designing, developing, manufacturing and marketing advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implants® line is sold in more than 60 countries worldwide. Puregraft® is an FDA-cleared and CE-marked technology that provides plastic surgeons with purified fat for reinjection on the sterile field. The company intends to use the $18M financing to launch Motiva Implants and Puregraft in some of the largest markets worldwide. Over the last six months the company has received regulatory clearances in Russia, Australia, Saudi Arabia, Israel, Vietnam and Brazil, among others. Establishment Labs is currently scaling up production capacity at its manufacturing plant in Costa Rica. Establishment Labs develops, manufactures and markets the CE-marked Motiva Implants® line and a portfolio of advanced silicone-filled breast and body shaping implants. The Motiva Implants® are manufactured in compliance with ISO and EU requirements and certified under Medical Device Directive 93/42/EEC. Led by CEO Juan José Chacón Quirós, the company is focused on expanding its Motiva Implants® in international markets. Establishment Labs secured up to $15m in debt funding to strengthen its financial position. The company plans to use the funds to finalize a new manufacturing facility and to start United States Food and Drug Administration trials. The financing supports both operational stability and product expansion efforts. Establishment Labs, based in Alajuela, Costa Rica and led by CEO Juan José Chacón-Quirós, designs, develops, manufactures and markets advanced silicone-filled breast and body shaping implants. Its CE-marked Motiva Implant Matrix® line is produced under ISO and EU requirements and is certified under Medical Device Directive 93/42/EEC. Motiva implants include features such as RFID microtransponders, fully biocompatible nanosurfaces, and TrueTissue™ dynamics and carry an extended product guarantee through Lloyd’s of London. Products are scrutinized by professional Quality Engineers throughout the manufacturing process. Thousands of patients and plastic surgeons in over 50 countries across five continents are using Motiva implants. The company closed a $20M financing round and intends to use the funds to accelerate investment in technology, grow its customer base, and scale the business.

Led · Equity · Aug 2017

BioQ Pharma is a San Francisco, CA-based specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceutical and biological products for rapid deployment at the point of care. The company is ISO13485 certified and maintains commercial collaborations and strategic partnerships with organizations including Novartis’ Sandoz unit, Cipla, Lee’s Pharm, Lunatus, Galen Limited, Pharma Mart, and West Pharmaceutical Services. Led by CEO Josh Krisel, BioQ has commercial operations that it intends to expand with new financing. It plans to use proceeds to support anticipated near-term regulatory approvals and to advance earlier-stage development activities. The company secured new financing of up to $55M from Madryn Asset Management, LP to support those initiatives.